Outlook Therapeutics is trading 5.07% lower at $0.56 as biotech and broader markets weaken; no clear company-specific catalyst for the October 8 decline was identified. - Biotech was down 2.04%, while the Nasdaq fell 1.27%. - The latest company press releases surfaced were dated October 6 and October 1. Elevated yields and rising oil prices are adding to risk-off pressure, but do not establish a company-specific catalyst.